Skip to main content

What is Braftovi used to treat?

Medically reviewed by Judith Stewart, BPharm. Last updated on Oct 16, 2023.

Official answer

by Drugs.com

Braftovi is used in combination with other drugs to treat patients with advanced melanoma, advanced non-small cell lung cancer (NSCLC) and advanced colorectal cancer with BRAF gene mutations.

Braftovi is an oral small molecule BRAF kinase inhibitor.

Melanoma

Braftovi (encorafenib) is used in combination with Mektovi (binimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Roughly 50% of patients diagnosed with metastatic melanoma test positive for the BRAF mutation, and it is the most common genetic mutation in metastatic melanoma.

Braftovi is not indicated for the treatment of patients with wild-type BRAF melanoma.

Colorectal Cancer

Braftovi is used in combination with Erbitux (cetuximab), for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

Braftovi is not indicated for treatment of patients with wild-type BRAF CRC.

BRAF mutations are estimated to occur in up to 15% of people with metastatic colorectal cancer.

Non-Small Cell Lung Cancer (NSCLC)

Braftovi is used in combination with Mektovi (binimetinib) to treat adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.

BRAF mutations are estimated to occur in 2% to 5% of people with metastatic non-small cell lung cancer.

Braftovi is not indicated for the treatment of patients with wild-type BRAF NSCLC.

References
  • Braftovi (encorafenib) prescribing information. Revised 10/2023. Pfizer Inc. New York, NY. Accessed Oct 16, 2023 at https://labeling.pfizer.com/ShowLabeling.aspx?id=12990

Related medical questions

Drug information

Related support groups